Article

Genotypic and Predicted Phenotypic Analysis of SARS-CoV-2 Omicron Subvariants in Immunocompromised Patients with COVID-19 Following Tixagevimab-Cilgavimab Prophylaxis

2022-11-04

Abstract excerpt

Background: Tixagevimab-cilgavimab is used for pre-exposure prophylaxis of COVID-19 in immunocompromised patients, though in vitro data has shown reduced neutralizing activity against SARS-CoV-2 Omicron subvariants.<br><br>Methods: We performed genomic sequencing of SARS-CoV-2 isolated from patients diagnosed with COVID-19 following tixagevimab-cilgavimab. Resistance-associated substitutions were used to generate...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5d002f86-7f9e-5b79-9448-6d4ca6f1eaf5
DOI: 10.2139/ssrn.4264150

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genotypic and Predicted Phenotypic Analysis of SARS-CoV-2 Omicron Subvariants in Immunocompromised Patients with COVID-19 Following Tixagevimab-Cilgavimab ProphylaxisDOI 10.2139/ssrn.4264150Read

Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxisSemantic proximity Read

Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.Semantic proximity Read

Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic DataSemantic proximity Read

Systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patientsSemantic proximity Read

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron SubvariantsSemantic proximity Read

Unveiling Protection: A Meta-Analysis of Tixagevimab-Cilgavimab Prophylaxis in 28,950 Transplant Recipients and Immunocompromised Patients Against COVID-19Semantic proximity Read

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineagesSemantic proximity Read

Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational studySemantic proximity Read

Resistance of SARS-CoV-2 Omicron Subvariant BA.4.6 to Antibody NeutralizationSemantic proximity Read

<i>In vitro</i> evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolateSemantic proximity Read

Real World Effectiveness of Tixagevimab/cilgavimab (Evusheld) in the Omicron EraSemantic proximity Read

Seroneutralization of Omicron BA.1 and BA.2 in patients receiving anti-SARS-CoV-2 monoclonal antibodiesSemantic proximity Read